Exenatide is a 39-amino-acid peptide; it is a synthetic version of Exendin-4, a hormone found in the saliva of the Gila monster. Exenatide was first isolated by John Eng in 1992 while working at the Veterans Administration Medical Center in the Bronx, New York. It is made by Amylin Pharmaceuticals and commercialized by AstraZeneca. Exenatide was approved by the FDA on April 28, 2005 for people whose diabetes was not well-controlled on other oral medication.  53 consolidated lawsuits against manufacturers of "GLP-1/DPP-4 products" were dismissed in 2015.